



**TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)**

Madrid, 20 December 2021

OTHER RELEVANT INFORMATION

In compliance with the reporting requirements provided for in article 227 of the Consolidated Text of the Securities Market Act, with regard to the inside information notice published on 3 November 2021 (under register number 1143) regarding a share buy-back programme (the “**Buy-back Programme**”), and in accordance with the provisions of sections 2 and 3 of article 2 of Commission Delegated Regulation 2016/1052, of 8 March 2016, Laboratorios Farmacéuticos ROVI, S.A. (“**ROVI**”), hereby informs that no transactions were performed by ROVI with own shares pursuant to the Buy-back Programme between 13 December 2021 and 17 December 2021.